仿制药-话题@MedSci

#仿制药#

261篇内容 | 5522人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1261334, encodeId=8b44126133482, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=国办印发文件开展仿制药质量和疗效一致性评价, objectType=article, longId=64518, objectId=cd7e6451889, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd7e6451889, replyNumber=0, likeNumber=86, createdTime=2016-03-10, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd7e6451889, moduleTitle=国办印发文件开展仿制药质量和疗效一致性评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd7e6451889)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261333, encodeId=4be1126133314, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=我国明确仿制药质量和疗效需达到与原研药一致, objectType=article, longId=64393, objectId=2fcb643937c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fcb643937c, replyNumber=0, likeNumber=83, createdTime=2016-03-08, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fcb643937c, moduleTitle=我国明确仿制药质量和疗效需达到与原研药一致, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fcb643937c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261332, encodeId=2fee12613323c, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=辣点评：仿制药申报更佳时机真到了吗？, objectType=article, longId=60262, objectId=0f2f60262ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f2f60262ea, replyNumber=0, likeNumber=54, createdTime=2015-12-05, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f2f60262ea, moduleTitle=辣点评：仿制药申报更佳时机真到了吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f2f60262ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261331, encodeId=357e126133146, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=关于开展仿制药质量和疗效一致性评价的意见（征求意见稿）, objectType=article, longId=59186, objectId=0eb55918655, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0eb55918655, replyNumber=0, likeNumber=52, createdTime=2015-11-22, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0eb55918655, moduleTitle=关于开展仿制药质量和疗效一致性评价的意见（征求意见稿）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0eb55918655)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261330, encodeId=710012613305b, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=FDA提速新药审批仿制药将被洗牌, objectType=article, longId=54580, objectId=446954580f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=446954580f1, replyNumber=0, likeNumber=53, createdTime=2015-08-08, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=446954580f1, moduleTitle=FDA提速新药审批仿制药将被洗牌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=446954580f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261329, encodeId=50cb1261329ab, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=美国FDA批准生物仿制药Zarxio（非格司亭-sndz）上市, objectType=article, longId=47909, objectId=6d364e90940, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d364e90940, replyNumber=0, likeNumber=86, createdTime=2015-03-11, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d364e90940, moduleTitle=美国FDA批准生物仿制药Zarxio（非格司亭-sndz）上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d364e90940)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261328, encodeId=422e1261328e6, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=赛诺菲的Toujeo能取代甘精胰岛素来得时（Lantus），并成为其它生物仿制药的杀手吗？, objectType=article, longId=47668, objectId=656f4e668a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=656f4e668a5, replyNumber=0, likeNumber=91, createdTime=2015-03-05, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=656f4e668a5, moduleTitle=赛诺菲的Toujeo能取代甘精胰岛素来得时（Lantus），并成为其它生物仿制药的杀手吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=656f4e668a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261326, encodeId=cef21261326b9, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=国务院重申公立医院药品采购规则：达到国际水平仿制药优先, objectType=article, longId=47589, objectId=a5404e589d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5404e589d7, replyNumber=0, likeNumber=57, createdTime=2015-03-04, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5404e589d7, moduleTitle=国务院重申公立医院药品采购规则：达到国际水平仿制药优先, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5404e589d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261327, encodeId=f9bf126132e72, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle="Lantus之争"愈演愈烈-礼来计划5月在欧洲上市Lantus(来得时)仿制药, objectType=article, longId=47603, objectId=92564e60345, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92564e60345, replyNumber=0, likeNumber=67, createdTime=2015-03-04, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92564e60345, moduleTitle="Lantus之争"愈演愈烈-礼来计划5月在欧洲上市Lantus(来得时)仿制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92564e60345)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261325, encodeId=86d61261325f5, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=FDA批准胃食管反流病第一个仿制药物Nexium上市申请, objectType=article, longId=46325, objectId=16c24632598, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16c24632598, replyNumber=0, likeNumber=58, createdTime=2015-01-30, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16c24632598, moduleTitle=FDA批准胃食管反流病第一个仿制药物Nexium上市申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16c24632598)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261324, encodeId=fde91261324df, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=诺华有望迎来美国上市的第一个生物仿制药, objectType=article, longId=45127, objectId=c0654512edd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0654512edd, replyNumber=0, likeNumber=74, createdTime=2015-01-09, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0654512edd, moduleTitle=诺华有望迎来美国上市的第一个生物仿制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0654512edd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261323, encodeId=309c1261323cc, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=ASH 2014：诺华filgrastim生物仿制药疗效媲美安进Neupogen, objectType=article, longId=43830, objectId=89874383047, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89874383047, replyNumber=0, likeNumber=60, createdTime=2014-12-12, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89874383047, moduleTitle=ASH 2014：诺华filgrastim生物仿制药疗效媲美安进Neupogen, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89874383047)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261322, encodeId=d532126132254, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=祸不单行，欧洲四国取消印度GVK Biosciences25种仿制药授权, objectType=article, longId=43722, objectId=319443e22c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=319443e22c5, replyNumber=0, likeNumber=79, createdTime=2014-12-10, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=319443e22c5, moduleTitle=祸不单行，欧洲四国取消印度GVK Biosciences25种仿制药授权, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=319443e22c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261321, encodeId=b5351261321ab, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=矿生物仿制药：Epirus联合兰伯西在印度推出Remicade生物仿制药, objectType=article, longId=43632, objectId=55054363267, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55054363267, replyNumber=0, likeNumber=67, createdTime=2014-12-07, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55054363267, moduleTitle=矿生物仿制药：Epirus联合兰伯西在印度推出Remicade生物仿制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55054363267)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261320, encodeId=b6331261320d4, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=安进Humira仿制药临床三期研究成功，Humira丧钟已响？, objectType=article, longId=42831, objectId=82f84283162, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82f84283162, replyNumber=0, likeNumber=63, createdTime=2014-11-21, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82f84283162, moduleTitle=安进Humira仿制药临床三期研究成功，Humira丧钟已响？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82f84283162)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261319, encodeId=aea3126131996, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=打开FDA大门的中国仿制药名录, objectType=article, longId=42613, objectId=f46e42613c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f46e42613c7, replyNumber=0, likeNumber=55, createdTime=2014-11-16, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f46e42613c7, moduleTitle=打开FDA大门的中国仿制药名录, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f46e42613c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261318, encodeId=c50b1261318fb, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=2014明星药物Humira及其仿制药, objectType=article, longId=41761, objectId=94c241e6147, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94c241e6147, replyNumber=0, likeNumber=64, createdTime=2014-10-29, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94c241e6147, moduleTitle=2014明星药物Humira及其仿制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94c241e6147)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261317, encodeId=204b126131e80, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=哥之父：支持仿制药的开发, objectType=article, longId=40851, objectId=62aa4085151, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62aa4085151, replyNumber=0, likeNumber=80, createdTime=2014-10-02, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62aa4085151, moduleTitle=哥之父：支持仿制药的开发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=62aa4085151)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261316, encodeId=a5be126131606, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=礼来旗下来得时仿制药Basaglar获FDA暂时批准, objectType=article, longId=39562, objectId=1bf73956249, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1bf73956249, replyNumber=0, likeNumber=87, createdTime=2014-08-27, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1bf73956249, moduleTitle=礼来旗下来得时仿制药Basaglar获FDA暂时批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1bf73956249)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261315, encodeId=57cd126131522, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=从贝达药业上市看中国仿制药困境, objectType=article, longId=37780, objectId=ca443e780cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca443e780cc, replyNumber=0, likeNumber=67, createdTime=2014-07-16, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca443e780cc, moduleTitle=从贝达药业上市看中国仿制药困境, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca443e780cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

仿制药

2020-05-29

drwjr (审核中...)

前往app查看评论内容

#仿制药#

国办印发文件开展仿制药质量和疗效一致性评价

2016-03-10

drwjr (审核中...)

前往app查看评论内容

#仿制药#

我国明确仿制药质量和疗效需达到与原研药一致

2016-03-08

drwjr (审核中...)

前往app查看评论内容

#仿制药#

辣点评：仿制药申报更佳时机真到了吗？

2015-12-05

drwjr (审核中...)

前往app查看评论内容

#仿制药#

关于开展仿制药质量和疗效一致性评价的意见（征求意见稿）

2015-11-22

drwjr (审核中...)

前往app查看评论内容

#仿制药#

FDA提速新药审批仿制药将被洗牌

2015-08-08

drwjr (审核中...)

前往app查看评论内容

#仿制药#

美国FDA批准生物仿制药Zarxio（非格司亭-sndz）上市

2015-03-11

drwjr (审核中...)

前往app查看评论内容

#仿制药#

赛诺菲的Toujeo能取代甘精胰岛素来得时（Lantus），并成为其它生物仿制药的杀手吗？

2015-03-05

drwjr (审核中...)

前往app查看评论内容

#仿制药#

国务院重申公立医院药品采购规则：达到国际水平仿制药优先

2015-03-04

drwjr (审核中...)

前往app查看评论内容

#仿制药#

"Lantus之争"愈演愈烈-礼来计划5月在欧洲上市Lantus(来得时)仿制药

2015-03-04

drwjr (审核中...)

前往app查看评论内容

#仿制药#

FDA批准胃食管反流病第一个仿制药物Nexium上市申请

2015-01-30

drwjr (审核中...)

前往app查看评论内容

#仿制药#

诺华有望迎来美国上市的第一个生物仿制药

2015-01-09

drwjr (审核中...)

前往app查看评论内容

#仿制药#

ASH 2014：诺华filgrastim生物仿制药疗效媲美安进Neupogen

2014-12-12

drwjr (审核中...)

前往app查看评论内容

#仿制药#

祸不单行，欧洲四国取消印度GVK Biosciences25种仿制药授权

2014-12-10

drwjr (审核中...)

前往app查看评论内容

#仿制药#

矿生物仿制药：Epirus联合兰伯西在印度推出Remicade生物仿制药

2014-12-07

drwjr (审核中...)

前往app查看评论内容

#仿制药#

安进Humira仿制药临床三期研究成功，Humira丧钟已响？

2014-11-21

drwjr (审核中...)

前往app查看评论内容

#仿制药#

打开FDA大门的中国仿制药名录

2014-11-16

drwjr (审核中...)

前往app查看评论内容

#仿制药#

2014明星药物Humira及其仿制药

2014-10-29

drwjr (审核中...)

前往app查看评论内容

#仿制药#

哥之父：支持仿制药的开发

2014-10-02

drwjr (审核中...)

前往app查看评论内容

#仿制药#

礼来旗下来得时仿制药Basaglar获FDA暂时批准

2014-08-27

drwjr (审核中...)

前往app查看评论内容

#仿制药#

从贝达药业上市看中国仿制药困境

2014-07-16

科室
- - 订阅+
  - 更多科室
工具
服务